MSLN and neoplasm: While anetumab ravtansine was not superior to vinorelbine, a post‐hoc analysis revealed that progression‐free and overall survival was substantially higher in patients treated with anetumab ravtansine who had MSLN membrane staining in > 50% of tumour cells compared to those who had MSLN staining in only 30–50% of tumour cells.15